SMART drugs

SMARTc develops in solid tumors, innovative entities, such as second (i.e. stealth) and third (i.e. targeted) generation liposomes. These nanodrugs present an optimized pharmacokinetic profile, with a more specific distribution towards cancer cells and could offer patients a higher efficacy with lower toxicities than standard anticancer agents.

rodallec you tube (1)

 

Third generation liposomes observed with TEM

Third generation liposomes observed with TEM

 

In vitro cancer cells uptake

In vitro cancer cells uptake

 

Efficacy tested on fluorescent and co-cultured spheroids (1)Efficacy tested on fluorescent and co-cultured spheroids (2).jpg

Efficacy tested on fluorescent and co-cultured spheroids

In vivo tumor uptake

In vivo tumor uptake

Link articles  :

Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer

Biodistribution, Tumor Uptake and Efficacy of 5-FU-Loaded Liposomes: Why Size Matters

In Vitro and In Vivo Evaluation of Lipofufol, a New Triple Stealth Liposomal Formulation of Modulated 5-Fu: Impact on Efficacy and Toxicity

In vitro and in vivo reversal of resistance to 5-fluorouracil in colorectal cancer cells with a novel stealth double-liposomal formulation

Development of Stealth Liposome Formulation of 2′-Deoxyinosine as 5-Fluorouracil Modulator: In Vitro and In Vivo Study

 

 

 

 

 

 

 

 

 

Leave A Reply

Phone: +33(0)491835509
Marseille 13005
Faculté de Pharmacie